

# Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease

NCT04873258

---

**Status** RECRUITING  
**Sponsor** Richmond Research Institute  
**Enrollment** 2,000 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Male or female volunteers aged e18 to d80 years at the date of signing the informed consent.
- Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations.
- An understanding, ability and willingness to fully comply with project procedures and restrictions.
- For PART B only:
- \. With a known history of MASLD as evidenced either of:  
... and 2 more (see full listing online)

### Exclusion (4)

- Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other)
- Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease)
- Alcohol consumption \>30 units per week
- An Implanted cardiac devices

## Locations (1 total)

---

Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge, London, London, United Kingdom